Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. [electronic resource]
Producer: 20150316Description: 172-9 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- administration & dosage
- Carcinoma, Hepatocellular -- drug therapy
- Drug Administration Schedule
- Female
- Hand-Foot Syndrome -- etiology
- Humans
- Hypertension -- chemically induced
- Indazoles -- administration & dosage
- Kaplan-Meier Estimate
- Liver Neoplasms -- drug therapy
- Male
- Middle Aged
- Niacinamide -- administration & dosage
- Odds Ratio
- Phenylurea Compounds -- administration & dosage
- Protein Kinase Inhibitors -- administration & dosage
- Receptor Protein-Tyrosine Kinases -- antagonists & inhibitors
- Risk Factors
- Sorafenib
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.